The concern of generic competition has consistently loomed above copyright’s famous drug, Viagra, raising questions about the future of related medicinal portfolios. While first years saw impressive gains, the intellectual property expiration has allowed the door for discounted copies, likely lowering earnings and posing a real hazard for stakeho